Despite encouraging clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant difficulty from pharmacy benefit managers. These organizations are often erecting limitations to access, such as steep expense requirements and approval processes that restrict consumer availa